Veracyte, Inc 8-K, filed Jul 16, 2021
Veracyte, Inc. (VCYT)
8-K
2021-07-16
For: 2021-07-13
View Original
Added on
April 11, 2026
About this 8-K
Veracyte, Inc filed this 8-K on July 16, 2021, reporting on events of July 13, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 13, 2021
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | Commission File Number | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) | (Zip Code) | |||||||
Registrant’s telephone number, including area code: (650 ) 243-6300
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | |||||
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. | ||
Emerging growth company | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | ||
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 13, 2021, James H. Erlinger III, Executive Vice President, General Counsel and Secretary of Veracyte, Inc. (the “Company”), announced his retirement from the Company, effective as of July 31, 2021.
In connection with Mr. Erlinger’s retirement, and in exchange for a standard release of claims consistent with Exhibit A to Mr. Erlinger’s Change of Control and Severance Agreement, which was filed as Exhibit 10.24 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 22, 2021 (File No. 001-36156), the Company has agreed to provide Mr. Erlinger with three months’ salary and a payment equivalent to three months’ continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: | July 16, 2021 | ||||||||||
VERACYTE, INC. | |||||||||||
By: | /s/ Marc Stapley | ||||||||||
Name: | Marc Stapley | ||||||||||
Title: | Chief Executive Officer | ||||||||||